Finbarr E. Cotter

BCL-2 antisense therapy in patients with non-Hodgkin lymphoma

Andrew Webb, David Cunningham, Finbarr E. Cotter et al. · The Lancet · 1997 · 498 citations

Medicine, Cancer Biology, Oncology +13

Phase I Clinical and Pharmacokinetic Study of Bcl-2 Antisense Oligonucleotide Therapy in Patients With Non-Hodgkin’s Lymphoma

Justin S. Waters, Andrew Webb, David Cunningham et al. · Journal of Clinical Oncology · 2000 · 456 citations

Medicine, Oncology, Pharmacology +13

Association of mutations in the <i>NALP3/CIAS1/PYPAF1</i> gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis

Ebun Aganna, Fabio Martinon, Philip N. Hawkins et al. · Arthritis & Rheumatism · 2002 · 374 citations

Life Sciences, Genetics, Molecular Genetics +13

The 11q terminal deletion disorder: A prospective study of 110 cases

Paul Grossfeld, Teresa Mattina, Zona Lai et al. · American Journal of Medical Genetics Part A · 2004 · 343 citations

Life Sciences, Genetics, Molecular Genetics +16

First demonstration of anti-lymphoma activity of BCL-2 antisense molecule-G3139; Results of phase I/IIA clinical trial

Amy Webb, David Cunningham, Finbarr E. Cotter et al. · European Journal of Cancer · 1997 · 320 citations

Medicine, Oncology, Pharmacology +12